Massachusetts-backed Isis Pharmaceuticals receives $3.5m milestone payment from Biogen for battle against spinal muscular atrophy.

Isis Pharmaceuticals has been awarded a $3.5m milestone payment from Biogen Idec after the firm’s success in dosing its first patient with a treatment aimed at curing infants with spinal muscular atrophy (SMA).

The Calif.-based firm uses intellectual property licensed from the University of Massachusetts Medical School, as well as IP developed at research centre Cold Spring Harbor Laboratory.

The first treatment marks phase 2 of the study of the SMA treatment, ISIS-SMRrx, which is an “open-label, multiple-dose, dose-escalation pilot…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?